The airway hematoma in our patient was believed to be due to the following two factors: 1) a difficulty in securing blood vessels for replacement therapy with efraloctocog alfa, resulting in a change in administration from twice a week to once a week and a decrease in FVIII activity, and 2) mucosal damage due to upper respiratory tract infection. This evidence concerns the gene F8 and Recurrent upper respiratory tract infections.